Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 3, pp 629–633 | Cite as

Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia

  • Yoshitaka Nishikawa
  • Taro Funakoshi
  • Takahiro Horimatsu
  • Shin’ichi Miyamoto
  • Takeshi Matsubara
  • Motoko Yanagita
  • Shunsaku Nakagawa
  • Atsushi Yonezawa
  • Kazuo Matsubara
  • Manabu Muto
Short Communication

Abstract

Purpose

High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal. However, the mechanism of 5FU-associated hyperammonemia has not been known. The aim of this study was to reveal the pharmacokinetics of 5-FU-associated hyperammonemia in a recurrent colorectal cancer patient with end-stage renal disease (ESRD).

Methods

We experienced a case of hyperammonemia during mFOLFOX6 plus bevacizumab therapy for recurrent colorectal cancer. He was a dialyzed patient due to diabetic nephropathy and was registered to prospective blood sampling for pharmacokinetics analysis during chemotherapy. Blood concentrations of 5-FU and its catabolites were determined by inductively coupled plasma-mass spectrometry.

Results

The patient developed hyperammonemia encephalopathy 41 h after the initiation of continuous 5-FU infusion (on the third day). Before onset of hyperammonemia encephalopathy, serum alpha-fluoro-beta-alanine (FBAL, 59.2 µg/ml) and fluoro mono acetate (FMA, 905.8 ng/ml) were gradually increased. After hemodialysis for hyperammonemia, FBAL and FMA were collaterally decreased and his symptom was improved. Other intermediate catabolites of 5-FU, dihydrofluorouracil, and alpha-fluoro-beta-ureidopropionic acid were not changed.

Conclusion

We found increases of serum FBAL and FMA under the condition of hyperammonemia in the patient with ESRD during mFOLFOX6 plus bevacizumab therapy. This research supported the hypothesis that impairment of tricarboxylic acid (TCA) cycle by FMA would cause 5-FU-associated hyperammonemia.

Keywords

5-Fluorouracil Hyperammonemia End-stage renal disease Pharmacokinetics 

Supplementary material

280_2017_3249_MOESM1_ESM.tif (5.9 mb)
Catabolism of 5-FU and hypothetic pathway of developing hyperammonemia during 5-FU-based chemotherapy. Abbreviations: FDHU dihydrofluorouracil, FUPA alpha-fluoro-beta-ureidopropionic acid, FBAL alpha-fluoro-beta-alanine, FMA fluoro mono acetate, DPD dihydropyrimidine dehydrogenase, and TCA cycle tricarboxylic acid cycle. (TIF 6077 KB)

References

  1. 1.
    Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664CrossRefPubMedGoogle Scholar
  2. 2.
    Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155–160. doi:10.1001/archneur.1970.00480260061008 CrossRefPubMedGoogle Scholar
  3. 3.
    Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nakamura M, Kobashikawa K, Tamura J et al (2009) A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer. Nihon Shokakibyo Gakkai Zasshi 106:1744–1750. doi:10.11405/nisshoshi.106.1744 PubMedGoogle Scholar
  5. 5.
    Misumi N, Goto T, Miyoshi T et al (2013) Risk factors for hyperammonemia during mFOLFOX6 treatment. Gan To Kagaku Ryoho 40:483–487PubMedGoogle Scholar
  6. 6.
    Iida T, Wagatsuma K, Tani M et al (2015) Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis. Nihon Shokakibyo Gakkai Zasshi 112:287–296. doi:10.11405/nisshoshi.112.287 PubMedGoogle Scholar
  7. 7.
    Horimatsu T, Miyamoto S, Morita S et al (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68:263–266. doi:10.1007/s00280-011-1633-9 CrossRefPubMedGoogle Scholar
  8. 8.
    Gamelin E, Delva R, Jacob J et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–2105. doi:10.1200/JCO.2007.13.3934 CrossRefPubMedGoogle Scholar
  9. 9.
    Kikuta S, Asakage T, Nakao K et al (2008) The aggravating factors of hyperammonemia related to 5-fluorouracil infusion–a report of two cases. Auris Nasus Larynx 35:295–299. doi:10.1016/j.anl.2007.04.012 CrossRefPubMedGoogle Scholar
  10. 10.
    Heggie GD, Sommadossi JP, Cross DS et al (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206PubMedGoogle Scholar
  11. 11.
    Thiberville L, Compagnon P, Moore N et al (1994) Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 35:64–70CrossRefPubMedGoogle Scholar
  12. 12.
    Casale F, Canaparo R, Serpe L et al (2004) Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50:173–179. doi:10.1016/j.phrs.2004.01.006 CrossRefPubMedGoogle Scholar
  13. 13.
    Lichtman SM, Wildiers H, Launay-Vacher V et al (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34. doi:10.1016/j.ejca.2006.11.004 CrossRefPubMedGoogle Scholar
  14. 14.
    Janus N, Thariat J, Boulanger H et al (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395–1403. doi:10.1093/annonc/mdp598 CrossRefPubMedGoogle Scholar
  15. 15.
    Bocci G, Danesi R, Allegrini G et al (2002) Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol 58:593–595. doi:10.1007/s00228-002-0534-6 CrossRefPubMedGoogle Scholar
  16. 16.
    van Kuilenburg AB, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705–4712PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Yoshitaka Nishikawa
    • 1
    • 2
  • Taro Funakoshi
    • 1
  • Takahiro Horimatsu
    • 1
  • Shin’ichi Miyamoto
    • 3
  • Takeshi Matsubara
    • 4
  • Motoko Yanagita
    • 4
  • Shunsaku Nakagawa
    • 5
  • Atsushi Yonezawa
    • 5
  • Kazuo Matsubara
    • 5
  • Manabu Muto
    • 1
  1. 1.Department of Therapeutic Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Department of Health Informatics, School of Public HealthKyoto University Yoshida-KonoeKyotoJapan
  3. 3.Department of Gastroenterology and Hepatology, Graduate School of MedicineKyoto UniversityKyotoJapan
  4. 4.Department of Nephrology, Graduate School of MedicineKyoto UniversityKyotoJapan
  5. 5.Department of Clinical Pharmacology and TherapeuticsKyoto University HospitalKyotoJapan

Personalised recommendations